Gastric Ulcers Market Report 2026

Gastric Ulcers Market Overview

• Gastric Ulcers market size has reached to $4.53 billion in 2025 • Expected to grow to $5.78 billion in 2030 at a compound annual growth rate (CAGR) of 4.9% • Growth Driver: Increasing Geriatric Population Fuels Gastric Ulcers Market Growth • Market Trend: Advancements In Drug Delivery Systems For Enhanced Efficacy And Safety • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Gastric Ulcers Market?

Gastric ulcers, also known as peptic ulcers, are open sores on the stomach's inner lining due to the corrosive action of stomach acid. They often cause burning stomach pain, indigestion, and discomfort. Gastric ulcers are usually caused by an imbalance between stomach acid, an enzyme called pepsin, and the protective mucosal barrier lining the stomach and duodenum. The main types of drug classes in gastric ulcers are proton pump inhibitors (PPI), h2 antagonists, antacids, antibiotics, cytoprotective agents, and others. Proton pump inhibitors (PPI) refer to a class of medications that reduce stomach acid production by inhibiting the proton pump enzyme in gastric cells. Medications that reduce stomach acid production. These ulcers can be diagnosed by stool tests, endoscopies, imaging tests, computed tomography (CT) scans, x-rays, blood tests, and others, and include various routes of administration such as oral, parenteral, and others. Several distribution channels include mainly hospital pharmacies, retail pharmacies, online pharmacies, and others, and are used by various end-users such as hospitals, specialty clinics, homecare, and others.

What Is The Gastric Ulcers Market Growth Forecast?

The gastric ulcers market size is expected to see steady growth in the next few years. It will grow to $5.78 billion in 2030 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to development of advanced acid-suppression drugs, demand for long-term ulcer management, growth in outpatient care, improved diagnostic technologies, increased lifestyle-related disorders. Major trends in the forecast period include increased use of proton pump inhibitors, rising focus on helicobacter pylori eradication, growth in combination drug therapies, expansion of non-invasive diagnostic methods, increased awareness of gastrointestinal disorders.

Global Gastric Ulcers Market Segmentation

1) By Drug Class: Proton Pump Inhibitors (PPI), H2 Antagonists, Antacids, Antibiotics, Cytoprotective Agents, Other Drug Classes 2) By Diagnosis: Stool Test, Endoscopy, Imaging Tests, Computed Tomography (CT) Scan, X-ray, Blood Tests, Other Diagnosis 3) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels 5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users Subsegments: 1) By Proton Pump Inhibitors (PPI): Omeprazole, Lansoprazole, Pantoprazole, Esomeprazole, Rabeprazole 2) By H2 Antagonists: Ranitidine, Famotidine, Cimetidine, Nizatidine 3) By Antacids: Calcium Carbonate, Magnesium Hydroxide, Aluminum Hydroxide, Sodium Bicarbonate 4) By Antibiotics: Amoxicillin, Clarithromycin, Metronidazole, Tetracycline 5) By Cytoprotective Agents: Sucralfate, Misoprostol, Bismuth Subsalicylate 6) By Other Drug Classes: Prostaglandin Analogues, Prokinetic Agents, Herbal And Alternative Medications, Combination Therapies

What Is The Driver Of The Gastric Ulcers Market?

The increasing geriatric population is expected to propel the growth of the gastric ulcers market going forward. The geriatric population refers to individuals typically aged 65 years and older, characterized by specific health considerations related to aging. The increase in the geriatric population is due to advancements in healthcare, leading to longer life expectancy and declining birth rates in many regions globally. Gastric ulcers are common in the geriatric population due to increased use of NSAIDs and decreased mucosal protection, often leading to higher risks of complications. For instance, in January 2024, according to the Population Reference Bureau (PRB), a US-based private non-profit organization, the population of Americans aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, representing a 47% increase. Additionally, this age group's proportion of the total population is anticipated to rise from 17% to 23%. This shift indicates a significant aging trend in the U.S. population. The projections highlight the increasing importance of addressing the needs of older adults in various sectors. Therefore, the increasing geriatric population is driving the growth of the gastric ulcers industry.

Key Players In The Global Gastric Ulcers Market

Major companies operating in the gastric ulcers market are Pfizer Inc., Merck & Co Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Co. Ltd, Boehringer Ingelheim, Viatris Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd, Cadila Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Yuhan Corporation, Daewoong Pharmaceutical Co. Ltd, Cadila Healthcare Ltd, Novitium Pharma LLC

Global Gastric Ulcers Market Trends and Insights

Major companies operating in the gastric ulcer market are focusing on developing innovative products, such as new formulations of drugs, to enhance treatment efficacy and reduce side effects. New formulation drugs refer to medications that are developed with innovative combinations of active ingredients, delivery systems, or dosage forms to improve their effectiveness, safety, and patient compliance. For instance, in June 2024, Akums Drugs and Pharmaceuticals Ltd., an India-based pharmaceutical preparation manufacturing company, launched Rabeprazole + Levosulpiride SR Capsules to provide enhanced relief for conditions such as gastro-oesophageal reflux disease (GERD) and other gastrointestinal tract (GIT) disorders. These products combine a proton pump inhibitor and a prokinetic agent, effectively treating gastrointestinal disorders such as gastroesophageal reflux disease (GERD) and gastric ulcers. This formulation not only reduces gastric acid secretion but also enhances gastric motility, providing comprehensive relief from symptoms like heartburn and indigestion.

What Are Latest Mergers And Acquisitions In The Gastric Ulcers Market?

In July 2024, Dr. Reddy’s Laboratories, an India-based pharmaceutical company specializing in branded and generic medicines, partnered with Takeda Pharmaceutical Company for Vonoprazan. With this deal, Dr. Reddy’s aims to commercialize Takeda’s next-generation potassium-competitive acid blocker in India, thereby strengthening its gastrointestinal portfolio with a therapy indicated for acid peptic disorders, including gastric ulcer, duodenal ulcer, and Helicobacter pylori-associated disease. Vonoprazan, developed by Takeda, is an orally active acid suppressant used for treating acid-related gastrointestinal conditions.

Regional Outlook

North America was the largest region in the gastric ulcers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Gastric Ulcers Market?

The gastric ulcers market consists of revenues earned by entities through barium swallow, H. pylori testing, and biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastric ulcers market also includes sales of amoxicillin, clarithromycin, metronidazole, omeprazole, and lansoprazole. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Gastric Ulcers Market Report 2026?

The gastric ulcers market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the gastric ulcers industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.